Figure S7 from In Vivo Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Pharmacodynamic Staining of T-Dxd with and without HALA Carrier Dose. Images of high HER2 expression NCI-N87 tumors with 6.4 mg/kg of T-Dxd (top) or 6.4 mg/kg of T-Dxd +32 mg/kg S12 carrier dose (5:1 ratio, bottom). The pharmacodynamic signal from γH2AX (red) in sections of tumor distal from ADC staining (green) indicate the bystander effect of T-DXd. However, some regions containing tumor cells had low levels of DNA damage (top). The staining intensity is lower but more uniform with the addition of the S12 HALA antibody (bottom).
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Nanoparticle-Based Drug Delivery
Radiopharmaceutical Chemistry and Applications
Publication details
- Publication date
- 2 April 2026
- Language
- EN